These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17322161)

  • 41. High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy.
    Kim YE; Woo HI; On YK; Kim JS; Lee SY
    Eur J Clin Nutr; 2015 Jun; 69(6):703-6. PubMed ID: 25828628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes.
    Kim E; Sy-Cordero A; Graf TN; Brantley SJ; Paine MF; Oberlies NH
    Planta Med; 2011 Feb; 77(3):265-70. PubMed ID: 20717876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Of blood, bones, and broccoli: warfarin-vitamin K interactions.
    Neafsey P
    Home Healthc Nurse; 2004 Mar; 22(3):178-82; quiz 183-4. PubMed ID: 15017321
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
    Gulseth MP; Grice GR; Dager WE
    Am J Health Syst Pharm; 2009 Jan; 66(2):123-33. PubMed ID: 19139476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic and environmental risk factors for oral anticoagulant overdose.
    Verstuyft C; Robert A; Morin S; Loriot MA; Flahault A; Beaune P; Funck-Brentano C; Jaillon P; Becquemont L
    Eur J Clin Pharmacol; 2003 Mar; 58(11):739-45. PubMed ID: 12634980
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Possible interaction between pomegranate juice and warfarin.
    Jarvis S; Li C; Bogle RG
    Emerg Med J; 2010 Jan; 27(1):74-5. PubMed ID: 20029019
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.
    Sconce EA; Kamali F
    Eur J Haematol; 2006 Dec; 77(6):457-62. PubMed ID: 17042764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
    Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T
    Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
    Spangler ML; Saxena S
    Clin Ther; 2010 Jan; 32(1):53-6. PubMed ID: 20171411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A potential interaction between warfarin and atovaquone.
    Hidalgo K; Lyles A; Dean SR
    Ann Pharmacother; 2011 Jan; 45(1):e3. PubMed ID: 21189363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
    Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
    J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic.
    Ghaswalla PK; Harpe SE; Tassone D; Slattum PW
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):352-60. PubMed ID: 23089199
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacogenomics and warfarin therapy.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibitory Effects of Cranberry Juice and Its Components on Intestinal OATP1A2 and OATP2B1: Identification of Avicularin as a Novel Inhibitor.
    Morita T; Akiyoshi T; Tsuchitani T; Kataoka H; Araki N; Yajima K; Katayama K; Imaoka A; Ohtani H
    J Agric Food Chem; 2022 Mar; 70(10):3310-3320. PubMed ID: 35230114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.